Imeik Technology Development Co (300896) - Net Assets
Based on the latest financial reports, Imeik Technology Development Co (300896) has net assets worth CN¥8.16 Billion CNY (≈ $1.19 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.91 Billion ≈ $1.30 Billion USD) and total liabilities (CN¥743.43 Million ≈ $108.79 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300896 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.16 Billion |
| % of Total Assets | 91.65% |
| Annual Growth Rate | 50.95% |
| 5-Year Change | 62.33% |
| 10-Year Change | 2975.26% |
| Growth Volatility | 160.49 |
Imeik Technology Development Co - Net Assets Trend (2014–2025)
This chart illustrates how Imeik Technology Development Co's net assets have evolved over time, based on quarterly financial data. Also explore 300896 asset base for the complete picture of this company's asset base.
Annual Net Assets for Imeik Technology Development Co (2014–2025)
The table below shows the annual net assets of Imeik Technology Development Co from 2014 to 2025. For live valuation and market cap data, see 300896 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥8.16 Billion ≈ $1.19 Billion |
+2.70% |
| 2024-12-31 | CN¥7.95 Billion ≈ $1.16 Billion |
+22.59% |
| 2023-12-31 | CN¥6.49 Billion ≈ $948.97 Million |
+9.07% |
| 2022-12-31 | CN¥5.95 Billion ≈ $870.05 Million |
+18.21% |
| 2021-12-31 | CN¥5.03 Billion ≈ $736.01 Million |
+11.00% |
| 2020-12-31 | CN¥4.53 Billion ≈ $663.06 Million |
+583.75% |
| 2019-12-31 | CN¥662.70 Million ≈ $96.97 Million |
+63.74% |
| 2018-12-31 | CN¥404.74 Million ≈ $59.23 Million |
+23.28% |
| 2017-12-31 | CN¥328.31 Million ≈ $48.04 Million |
+23.66% |
| 2016-12-31 | CN¥265.49 Million ≈ $38.85 Million |
+75.06% |
| 2015-12-31 | CN¥151.66 Million ≈ $22.19 Million |
+72.23% |
| 2014-12-31 | CN¥88.06 Million ≈ $12.89 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Imeik Technology Development Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5704.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.16 Billion | 54.84% |
| Common Stock | CN¥302.59 Million | 3.99% |
| Other Components | CN¥3.12 Billion | 41.17% |
| Total Equity | CN¥7.58 Billion | 100.00% |
Imeik Technology Development Co Competitors by Market Cap
The table below lists competitors of Imeik Technology Development Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Protagonist Therapeutics Inc
NASDAQ:PTGX
|
$5.09 Billion |
|
OHB SE
XETRA:OHB
|
$5.09 Billion |
|
ShenZhen YUTO Packaging Technology Co Ltd
SHE:002831
|
$5.10 Billion |
|
Lagercrantz Group AB (publ)
ST:LAGR-B
|
$5.10 Billion |
|
Big Shopping Centers Ltd
TA:BIG
|
$5.09 Billion |
|
COSCO SHIPPING Holdings Co. Ltd
F:C6G
|
$5.09 Billion |
|
Macy’s Inc
NYSE:M
|
$5.09 Billion |
|
SIGMASTAR TECH LTD
SHE:301536
|
$5.09 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Imeik Technology Development Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,797,060,228 to 7,583,951,049, a change of -213,109,179 (-2.7%).
- Net income of 1,291,017,682 contributed positively to equity growth.
- Dividend payments of 1,507,130,935 reduced retained earnings.
- Other comprehensive income decreased equity by 131,592,751.
- Other factors increased equity by 134,596,825.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.29 Billion | +17.02% |
| Dividends Paid | CN¥1.51 Billion | -19.87% |
| Other Comprehensive Income | CN¥-131.59 Million | -1.74% |
| Other Changes | CN¥134.60 Million | +1.77% |
| Total Change | CN¥- | -2.73% |
Book Value vs Market Value Analysis
This analysis compares Imeik Technology Development Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.57x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 32.92x to 4.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CN¥3.49 | CN¥115.05 | x |
| 2015-12-31 | CN¥5.12 | CN¥115.05 | x |
| 2016-12-31 | CN¥1.21 | CN¥115.05 | x |
| 2017-12-31 | CN¥1.43 | CN¥115.05 | x |
| 2018-12-31 | CN¥1.76 | CN¥115.05 | x |
| 2019-12-31 | CN¥2.90 | CN¥115.05 | x |
| 2020-12-31 | CN¥18.45 | CN¥115.05 | x |
| 2021-12-31 | CN¥16.61 | CN¥115.05 | x |
| 2022-12-31 | CN¥19.30 | CN¥115.05 | x |
| 2023-12-31 | CN¥21.01 | CN¥115.05 | x |
| 2024-12-31 | CN¥25.89 | CN¥115.05 | x |
| 2025-12-31 | CN¥25.16 | CN¥115.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Imeik Technology Development Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.02%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 53.26%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.17x
- Recent ROE (17.02%) is below the historical average (24.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 32.27% | 37.83% | 0.71x | 1.20x | CN¥19.61 Million |
| 2015 | 11.64% | 15.79% | 0.65x | 1.14x | CN¥2.49 Million |
| 2016 | 20.31% | 37.93% | 0.45x | 1.19x | CN¥27.09 Million |
| 2017 | 25.29% | 36.94% | 0.56x | 1.22x | CN¥49.69 Million |
| 2018 | 30.84% | 38.27% | 0.69x | 1.16x | CN¥83.01 Million |
| 2019 | 46.37% | 54.78% | 0.75x | 1.13x | CN¥239.63 Million |
| 2020 | 9.70% | 62.00% | 0.15x | 1.03x | CN¥-13.63 Million |
| 2021 | 19.05% | 66.16% | 0.27x | 1.05x | CN¥455.02 Million |
| 2022 | 21.61% | 65.17% | 0.31x | 1.07x | CN¥678.95 Million |
| 2023 | 29.28% | 64.77% | 0.42x | 1.08x | CN¥1.22 Billion |
| 2024 | 25.11% | 64.70% | 0.36x | 1.07x | CN¥1.18 Billion |
| 2025 | 17.02% | 53.26% | 0.27x | 1.17x | CN¥532.62 Million |
Industry Comparison
This section compares Imeik Technology Development Co's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $3,882,684,540
- Average return on equity (ROE) among peers: 11.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Imeik Technology Development Co (300896) | CN¥8.16 Billion | 32.27% | 0.09x | $5.09 Billion |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $858.96 Million | 5.81% | 3.43x | $523.48 Million |
| Blue Sail Medical Co Ltd (002382) | $9.55 Billion | -5.95% | 0.64x | $1.10 Billion |
| Andon Health Co Ltd (002432) | $21.49 Billion | 7.76% | 0.23x | $5.00 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $3.21 Billion | 3.44% | 0.58x | $1.28 Billion |
| Guangzhou Improve Med Instrument (300030) | $838.26 Million | 3.10% | 0.80x | $376.43 Million |
| QITIAN Technology Group Co Ltd (300061) | $451.92 Million | 8.13% | 0.70x | $924.78 Million |
| Shanghai Tofflon Science Tech (300171) | $113.69 Million | 40.44% | 1.35x | $1.47 Billion |
| Truking Technology Ltd (300358) | $1.67 Billion | 8.57% | 0.72x | $1.02 Billion |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $122.42 Million | 28.61% | 0.63x | $770.09 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $520.95 Million | 10.42% | 0.38x | $2.50 Billion |
About Imeik Technology Development Co
Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China. The company offers aesthetic medicine products, such as cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere; poly facial implant thread; medical sodium hyaluronate-hydroxypropyl methylcellulose gel; sodium hyaluronate compos… Read more